Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche's Rituxan that generated $7.5 billion in 2016 sales....NVS[...]
Novartis's medicine Rixathon is made by the company's generics unit Sandoz and aims to lure business away from Roche's medicine, also known as MabThera, with a lower price.[...]
Sandoz weighs into European rituximab biosimilar market[...]


Star ActiveStar ActiveStar ActiveStar ActiveStar Inactive